FDA Approves Three-Times-A-Week Copaxone

Today Teva Pharmaceuticals Industries Ltd. received approval from the US Food and Drug Administration to market a long-acting version of Copaxone (glatiramer acetate) for the treatment of relapsing forms of multiple sclerosis.

The new 40mg/mL formulation of Copaxone will provide patients with a less frequent, three-times-a-week dosing regimen. Approval was based on results from the Phase III Glatiramer Acetate Low-Frequency Administration (GALA) study, which included more than 1,400 patients with relapsing-remitting MS. It was shown that the 40mg/mL dose of Copaxone significantly reduced relapse rates at twelve months when administered subcutaneously three-times-a-week. Copaxone 40mg/mL demonstrated a favorable safety and tolerability profile.

Teva expects the new 40mg/mL dose of Copaxone to be available for patient use within days. The current 20mg/mL of Copaxone, will still be available for daily use, although generic options are anticipated in the coming months.

By providing your email address, you are agreeing to our privacy policy.

Join the conversation

or create an account to comment.

Community Poll

How well do people around you understand MS?